Loading clinical trials...

PET Imaging of MMP Activation in AAA: Clinical Component | Clinical Trials | Clareo Health

RECRUITINGEARLY_PHASE1

PET Imaging of MMP Activation in AAA: Clinical Component

NCT07473102•Washington University School of Medicine

Summary

A first-in-human evaluation of \[64Cu\]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).

Detailed Description

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions.
•Able to comprehend and willing to follow instructions for the study procedures as called for by the protocol.
•Capable of lying still and supine within the PET/CT scanner for \~1 hour and follow instructions for breathing protocol during the CT portion.
•No illicit drug use or other inhaled drug use (including pharmacologic agents, recreational agents, or illicit drugs) within the past year.
•No known history of cardiac, pulmonary, hepatic or renal disease or diabetes
•BMI ≤ 40
•Men or women 40-80 years of age
•Willing and able to provide informed consent
•Medically managed hypertension and hyperlipidemia
•No history of claustrophobia or other preventing condition that has previously or would interfere with completion of protocol-specified imaging sessions
+2 more criteria

Exclusion Criteria

•Inability to receive and sign informed consent;
•Pregnant (confirmed by urine pregnancy test) and/or breastfeeding
•Patient with chronic renal disease whose glomerular filtration rate (GFR) is less than 30 mL/min/1.73 m2
•Patients with an unstable clinical condition that in the opinion of the principal investigators or designee precludes participation in the study.
•Is deemed likely to be unable to perform all research procedures for any reason, (e.g., subjects unable to lie still or inability to tolerate up to 60 minutes in a supine position with arms up during the PET imaging procedures due to chronic back/shoulder pain or arthritis as assessed by physical examination and medical history).
•Currently using recreational drugs.
•Body weight of \>300 lbs. (weight limit of the PET table).
•Currently enrolled in another study using an investigational drug or underwent a study the last year involving investigational use of radiotracers or CT would confound results or with a radiation exposure when combined with this study would be deemed as excessive by the Sponsor-Investigator.
•Inability to receive and sign informed consent.
•Currently enrolled in another study using an investigational drug
+7 more criteria

Locations (1)

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

November 3, 2025

Primary Completion Date

March 31, 2027

Completion Date

March 31, 2027

Last Updated

March 18, 2026

Enrollment

ESTIMATED participants

Conditions

Abdominal Aortic Aneurysm

Interventions

Cu-64-RYM2

DRUG

PET imaging using Cu-64

DRUG

Contacts

Kitty Harrison, RN, BSN

CONTACT

314-747-0183 kittydharrison@wustl.edu

Robert Gropler, MD

CONTACT

314-747-0183 rgropler@wustl.edu

Terumo Aortic Global Endovascular Registry

NCT04246463

Abdominal Aortic AneurysmThoracic Aortic Aneurysm+1 more

View study

RECRUITING

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

NCT06218875

AAA - Abdominal Aortic Aneurysm

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 18, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

PET Imaging of MMP Activation in AAA: Clinical Component

Inclusion Criteria

Exclusion Criteria

Terumo Aortic Global Endovascular Registry

Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis

CAAAs, TAAAs, Aortic Arch Aneurysms or Dissections With Fenestrated/Branched Stent Graft

First-In-Human Study Evaluating Aneurysm Sac Lining in AAA Patients

Investigating Practice Patterns in Symptomatic Non-ruptured Abdominal Aortic Aneurysms (AAA) in Europe

Thoracoabdominal Artery Stent Graft System Exploratory Study